Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?

Improving Selection Criteria for ALK Inhibitor Therapy in Non–Small Cell Lung Cancer

(2016) Long Jiang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Clinical Validation of a Novel Commercial Reverse Transcription–Quantitative Polymerase Chain Reaction Screening Assay for Detection ofALKTranslocations and Amplifications in Non–Small Cell Lung Carcinomas

(2016) Chunyan Liu et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

A Multiplexed Amplicon Approach for Detecting Gene Fusions by Next-Generation Sequencing

(2016) Carol Beadling et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

(2016) Adrian G. Sacher et al.   JAMA Oncology

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)

(2015) K. Takeuchi et al.   ANNALS OF ONCOLOGY

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

(2015) R. Katayama et al.   CLINICAL CANCER RESEARCH

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients

(2015) C. P. Paweletz et al.   CLINICAL CANCER RESEARCH

French multicentric validation ofALKrearrangement diagnostic in 547 lung adenocarcinomas

(2015) Sylvie Lantuejoul et al.   EUROPEAN RESPIRATORY JOURNAL

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

(2015) Weijing Cai et al.   JOURNAL OF CLINICAL ONCOLOGY

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer

(2015) Toni-Maree Rogers et al.   Journal of Thoracic Oncology

Clinical Implications of Variant ALK FISH Rearrangement Patterns

(2015) Xin Gao et al.   Journal of Thoracic Oncology

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice

(2015) Vittoria Martin et al.   Journal of Thoracic Oncology

BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib

(2015) Ling Shan et al.   Journal of Thoracic Oncology

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer

(2015) Yan Wang et al.   Journal of Thoracic Oncology

ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making

(2015) Maximilian von Laffert et al.   LUNG CANCER

Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended

(2015) Spasenija Savic et al.   LUNG CANCER

Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK -rearranged non-small cell lung cancer (NSCLC)

(2015) Qin Shen et al.   LUNG CANCER

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group

(2015) Manfred Dietel et al.   THORAX

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer

(2014) K. M. Kerr et al.   ANNALS OF ONCOLOGY

Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma

(2014) Frida Rosenblum et al.   CANCER CYTOPATHOLOGY

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

(2014) Fiona H. Blackhall et al.   JOURNAL OF CLINICAL ONCOLOGY

A rare case of anEML4-ALK-rearranged lung adenocarcinoma missed by in situ-hybridisation but detected by RT-PCR

(2014) A Roth et al.   JOURNAL OF CLINICAL PATHOLOGY

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer

(2014) Shengxiang Ren et al.   Journal of Thoracic Oncology

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription Polymerase Chain Reaction Assay

(2014) Kim Gruber et al.   Journal of Thoracic Oncology

ALK Testing in Non-Small Cell Lung Carcinoma: What Now?

(2014) Keith M. Kerr   Journal of Thoracic Oncology

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances

(2014) Florian Cabillic et al.   Journal of Thoracic Oncology

Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry

(2014) Esther Conde et al.   PLoS One

Detection of Circulating Tumor Cells Harboring a Unique ALK Rearrangement in ALK-Positive Non–Small-Cell Lung Cancer

(2013) Emma Pailler et al.   JOURNAL OF CLINICAL ONCOLOGY

Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma

(2013) Harumi Nakamura et al.   JOURNAL OF CLINICAL PATHOLOGY

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

(2013) Neal I. Lindeman et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens

(2013) Colin C. Pritchard et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies

(2013) Yoshihisa Kobayashi et al.   Journal of Thoracic Oncology

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas

(2013) Lynette M. Sholl et al.   Journal of Thoracic Oncology

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

(2013) Tianhong Li et al.   Journal of Thoracic Oncology

Comparison of Reverse Transcription-Polymerase Chain Reaction, Immunohistochemistry, and Fluorescence In Situ Hybridization Methodologies for Detection of Echinoderm Microtubule-Associated Proteinlike 4–Anaplastic Lymphoma Kinase Fusion–Positive Non–Small Cell Lung Carcinoma: Implications for Optimal Clinical Testing

(2012) Michelle L. Wallander et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Diagnosis of Lung Cancer in Small Biopsies and Cytology: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification

(2012) William D. Travis et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification

(2012) William D. Travis et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer

(2012) D. Ross Camidge et al.   CANCER

Mechanisms of Resistance to Crizotinib in Patients withALKGene Rearranged Non–Small Cell Lung Cancer

(2012) Robert C. Doebele et al.   CLINICAL CANCER RESEARCH

Discordance between anaplastic lymphoma kinase status in primary non-small-cell lung cancers and their corresponding metastases

(2012) Hyojin Kim et al.   HISTOPATHOLOGY

Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer

(2012) Maruja E. Lira et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

A Novel Mass Spectrometry–Based Assay for Diagnosis of EML4-ALK–Positive Non–Small Cell Lung Cancer

(2012) Kazuko Sakai et al.   Journal of Thoracic Oncology

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK

(2012) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer

(2012) Nir Peled et al.   Journal of Thoracic Oncology

Crizotinib for the Treatment of ALK -Rearranged Non-Small Cell Lung Cancer: A Success Story to Usher in the Second Decade of Molecular Targeted Therapy in Oncology

(2012) Sai-Hong Ignatius Ou et al.   ONCOLOGIST

A Novel, Highly Sensitive Antibody Allows for the Routine Detection of ALK-Rearranged Lung Adenocarcinomas by Standard Immunohistochemistry

(2010) M. Mino-Kenudson et al.   CLINICAL CANCER RESEARCH

Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens

(2010) Peh Sun Loo et al.   Journal of Thoracic Oncology

Quantitative Analysis of Tumor in Bronchial Biopsy Specimens

(2010) Caroline L. Coghlin et al.   Journal of Thoracic Oncology

The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung

(2010) Esther Conde et al.   PLoS One